Oshkosh structures partnerships to own IP developed jointly with a startup, then licenses it back. This approach, outlined in the initial NDA, gives the large corporation control over patent defense while providing the startup with usage rights, often with market-specific limitations.

Dan Schmitt used his role as an Entrepreneur in Residence at Northwestern University to gain priority access to new technologies. This strategic position allowed him to secure the foundational asset for Actuate Therapeutics, directly bridging academic innovation with commercial enterprise.

When fundraising, the most critical choice isn't the VC fund's brand but the specific partner who will join the board. Sophisticated founders vet the individual's strengths, weaknesses, and working style, as that person has a more direct impact on the company than the firm's logo on a term sheet.

Institutional ownership of intellectual property can stifle a clinician's motivation to commercialize their idea. Dr. Adam Power advocates for an 'inventor-owned' IP model, arguing that no university department or tech transfer office will ever match the round-the-clock drive of the inventor themself.

A university's Tech Transfer Office (TTO) should not be viewed as an opponent. Michal Preminger notes that nearly every spinout eventually returns to the TTO asking for a favor, such as a milestone extension or access to new IP. A positive initial negotiation is crucial for this future relationship.

Eleven Labs learned that an effective first legal counsel for a startup must do more than just flag risks. A lawyer from a large corporate background paralyzed the company by only pointing out potential downsides. The right hire acts as a strategic partner who helps navigate the startup risk equation.

A 'champion' likes your product, but a 'coach' has the internal experience and political capital to navigate procurement, legal, and other departments. To qualify a coach, confirm they have successfully managed similar complex projects in the past and can protect you from internal minefields.

Founders pitching pharma must determine if their solution is being 'pulled' by a stated R&D priority or 'pushed' by an enthusiastic innovation scout. A 'pull' signifies a fast-track deal process, while a 'push' could mean a multi-year educational journey before any deal is possible.

Instead of jumping directly to an acquisition, de-risk the process by first establishing a partnership or licensing agreement. This allows you to test the technology, cultural fit, and market reception with a lower commitment, building a stronger foundation for a potential future deal.